Trials
1 active
1 in total
Targets
—
None known yet
What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “OCF001 is an antifungal antibiotic that is formulated in a water-miscible viscous gel at concentrations of 0.150 mg / g of gel.”In the company’s words, NCT07521137 on ClinicalTrials.gov
- Tested for
- Candidiasis, Vulvovaginal
- Main trialPhase 2
- “A Randomized, Double-Blind, Placebo-Controlled Phase 2a Study Evaluating the Safety, Tolerability, and Efficacy of OCF001 Intravaginal Gel in Women with Acute Vulvovaginal Candidiasis”In the company’s words, NCT07521137 on ClinicalTrials.gov
- Other names
- Occidiofungin
Other drugs for Candidiasis, Vulvovaginal
- Clotrimazole+LactuloseAVVA Pharmaceuticals Ltd. · Phase 2/3
- Candida VaccineLimmaTech Biologics AG · Phase 1/2
Coming up1
- 31 DecPhase 2 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials1
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 2Recruiting | 31 Dec 2026 | Biweekly Long-term Occidiofungin Study for Suppression of Mycotic Recurrence |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026